Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
暂无分享,去创建一个
M. Ladanyi | A. Drilon | Shunqi Yan | Gregory Riely | R. Somwar | Roger S Smith | Rupal A Patel | E. Martin | P. Multani | J. Joseph | G. Li | J. Oliver | G. Wei | J. Harris | A. Franovic | L. Martin | T. Hayashi | A. Schairer | James D. Joseph
[1] Ross Camidge,et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Kohno,et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. , 2017, The Lancet. Respiratory medicine.
[3] M. Ladanyi,et al. A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers , 2016, The Lancet. Oncology.
[4] A. Drilon,et al. A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors , 2016 .
[5] V. Velcheti,et al. Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung , 2016 .
[6] D. Coppola,et al. Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma , 2016, Molecular Cancer Therapeutics.
[7] Xi Zhang,et al. Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis , 2016, Expert review of clinical pharmacology.
[8] A. Drilon,et al. Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. , 2016 .
[9] T. Kohno,et al. A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. , 2016 .
[10] J. Ahn,et al. A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. , 2016 .
[11] A. Drilon,et al. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. , 2016 .
[12] L. Borsu,et al. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF , 2015, Molecular Cancer Research.
[13] M. Fakih,et al. Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers , 2015 .
[14] P. Stephens,et al. Identification and characterization of RET fusions in advanced colorectal cancer , 2015, Oncotarget.
[15] M. Ladanyi,et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. , 2015 .
[16] K. Kumamoto,et al. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. , 2014, Carcinogenesis.
[17] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[18] G. Krampitz,et al. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma , 2014, Cancer.
[19] L. Mulligan. RET revisited: expanding the oncogenic portfolio , 2014, Nature Reviews Cancer.
[20] Iwei Yeh,et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.
[21] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[22] Lu Wang,et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.
[23] C. Rudin,et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. , 2013 .
[24] J. Wolf,et al. Activated RET and ROS: two new driver mutations in lung adenocarcinoma. , 2013, Translational lung cancer research.
[25] Christopher D. Hart,et al. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer , 2013, OncoTargets and therapy.
[26] H. Ji,et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Deswarte,et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation , 2012, Leukemia.
[28] L. Mulligan,et al. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2 , 2012, Clinics.
[29] Seungbok Lee,et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.
[30] W. Pao,et al. Chipping away at the lung cancer genome , 2012, Nature Medicine.
[31] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[32] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.
[33] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[34] Raffaella Faraoni,et al. CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity , 2012, Molecular Cancer Therapeutics.
[35] A. Ghose,et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. , 2012, Journal of medicinal chemistry.
[36] S. Digumarthy,et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Brian T. Campbell,et al. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[38] T. Itoh,et al. Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo. , 2011, Cancer research.
[39] M. Shah,et al. Targeting RET Receptor Tyrosine Kinase Activation in Cancer , 2010, Clinical Cancer Research.
[40] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[41] M. Santoro,et al. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. , 2006, European journal of endocrinology.
[42] J. Minna,et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.
[43] M. Borrello,et al. RET tyrosine kinase signaling in development and cancer. , 2005, Cytokine & growth factor reviews.